Literature DB >> 7416026

Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway.

H J Wellens, F W Bär, W R Dassen, P Brugada, E J Vanagt, J Farré.   

Abstract

The effect of procainamide, quinidine, ajmaline and amiodarone on the effective refractory period of the accessory pathway in the (A-V) anterograde and retrograde directions was studied in relation to the length of this period before drug administration. All patients had the Wolff-Parkinson-White syndrome and were studied with intracavitary recordings and programmed electrical stimulation of the heart using identical basic cycle lengths and test stimulus intervals before and after drug administration. The patients were separated into two groups, those in whom the effective refractory period of the accessory pathway was 270 ms or greater (Group 1) and those in whom it was less than 270 (Group 2). In the anterograde direction the magnitude of increase in the length of the effective refractory period of the accessory pathway after drug administration was related to its initial length. Only modest lengthening of this period could be accomplished in patients with an initially short period. In evaluating the effect of drugs in patients with the Wolff-Parkinson-White syndrome, the role of the initial length of the effective refractory period of the accessory pathway should be considered.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7416026     DOI: 10.1016/0002-9149(80)90518-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Electrophysiologic evaluation of antiarrhythmic drugs.

Authors:  P Touboul
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 2.  Current management of the Wolff-Parkinson-White syndrome.

Authors:  A Arai; J Kron
Journal:  West J Med       Date:  1990-04

3.  Incessant junctional reciprocating tachycardia caused by dual atrioventricular nodal pathways and atrio-nodal bypass tract.

Authors:  P Santarelli; E Sosa; P Denes
Journal:  Br Heart J       Date:  1982-06

4.  Efficacy of sotalol in controlling reentrant supraventricular tachycardias.

Authors:  R N Millar
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

5.  Acceleration of the ventricular response to atrial flutter by amiodarone in an infant with Wolff-Parkinson-White syndrome.

Authors:  J A Till; M Baxendall; A Benetar
Journal:  Br Heart J       Date:  1993-07

6.  Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome.

Authors:  B D Sheinman; T Evans
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

Review 7.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

8.  Unmasking of left free wall ventricular preexcitation by His bundle ablation.

Authors:  A G Visman; R N Hauer; E O Robles de Medina
Journal:  Br Heart J       Date:  1993-05

Review 9.  Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.

Authors:  A Capucci; G Boriani
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

10.  Electrophysiological evaluation of Wolff-Parkinson-White syndrome.

Authors:  Beatrice Brembilla-Perrot
Journal:  Indian Pacing Electrophysiol J       Date:  2002-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.